Risk for gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologics

Arthritis & Rheumatism

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/1WhNtag
via IFTTT